Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Langzi Co., Ltd., indicating a stable growth in revenue and profit, alongside significant trading volumes in the stock market [1][2][3] Group 2 - As of June 30, 2025, Langzi Co., Ltd. reported a revenue of 2.788 billion yuan, representing a year-on-year growth of 3.69%, and a net profit attributable to shareholders of 274 million yuan, showing a substantial increase of 80.58% [2] - The company has cumulatively distributed 1.4 billion yuan in dividends since its A-share listing, with 376 million yuan distributed over the past three years [3] - The stock trading data on September 9 shows that Langzi Co., Ltd. had a financing buy-in amount of 33.03 million yuan and a net buy of 761,500 yuan, with a total financing balance of 1.85 billion yuan, which is 2.18% of its market capitalization [1]

证券代码：002612 证券简称：朗姿股份 公告编号：2025-053 朗姿股份有限公司 关于为全资子公司提供担保并接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第五届董事会第 二十九次会议和 2024 年度股东大会分别审议通过了《关于 2025 年度对外担保额 度的议案》，同意 2025 年度公司及其控股子公司的对外担保总额不超过 30.50 亿元（以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率 未超过 70%的控股子公司担保额度为 24.00 亿元，对资产负债率超过 70%的控股 子公司担保额度为 6.50 亿元。该担保额度的有效期自公司 2024 年度股东大会审 议批准本议案之日起至 2025 年度股东大会召开之日止。截至本公告披露日，公 司及控股子公司对外担保总余额为 106,216 万元，占公司 2024 年度经审计净资 产的 38.11%；其中，实际被担保方北京莱茵服装有限公司资产负债率超过 70%， 公司对资产负债率超过 70%的控股子公司 ...

Group 1 - The company announced that its wholly-owned subsidiary, Beijing Yiguan, applied for a loan of 70 million yuan from Pudong Development Bank, with the company providing a maximum joint liability guarantee [1] - Beijing Yiguan pledged 70% equity of Hunan Yamei as collateral for the loan [1] - The company's controlling shareholder, Shen Dongri, and his spouse, Weng Jie, provided a joint liability guarantee free of charge [1] Group 2 - The total amount of external guarantees provided by the company and its subsidiaries for the year 2025 is not to exceed 3.05 billion yuan [1] - As of the announcement date, the total balance of external guarantees provided by the company and its subsidiaries is 1.06216 billion yuan, accounting for 38.11% of the audited net assets for the year 2024 [1] - This guarantee is within the approved limit and will not negatively impact the company's operations or harm shareholder interests [1]

Company Overview - Langzi Co., Ltd. is located in Beijing and was established on November 9, 2006, with its listing date on August 30, 2011 [1] - The company specializes in the design, production, and sales of branded women's clothing, with revenue contributions from medical beauty (47.81%), fashion women's clothing (35.44%), green baby products (15.60%), and others (1.16%) [1] Stock Performance - As of September 8, Langzi's stock price increased by 2.05% to 18.88 CNY per share, with a total market capitalization of 8.353 billion CNY [1] - Year-to-date, the stock price has risen by 18.30%, with a 1.23% increase over the last five trading days, 5.95% over the last 20 days, and 6.07% over the last 60 days [1] Financial Performance - For the first half of 2025, Langzi reported a revenue of 2.788 billion CNY, representing a year-on-year growth of 3.69%, and a net profit attributable to shareholders of 274 million CNY, which is an increase of 80.58% year-on-year [2] - The company has distributed a total of 1.4 billion CNY in dividends since its A-share listing, with 376 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 57,700, with an average of 4,415 circulating shares per person, a decrease of 3.24% from the previous period [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.4247 million shares, a decrease of 1.9754 million shares from the previous period, while Southern CSI 1000 ETF increased its holdings by 395,900 shares to 2.0453 million shares [3]

Investment Rating - The report maintains a "Buy" rating for the cosmetics and medical beauty sector, highlighting strong growth potential and investment opportunities in the industry [14][19]. Core Insights - The cosmetics and medical beauty sector has shown resilience, outperforming the market during the week of August 29 to September 5, 2025, with the Shenwan Beauty Care Index declining only 0.8% [3][4]. - The transition to autumn skincare marks the beginning of a consumption peak for the sector, with significant sales events such as the Autumn Beauty Consumption Festival and Double 11 approaching, creating new investment opportunities [9][10]. - Major companies in the sector are optimistic about their performance in the second half of 2025, as indicated by a recent conference involving over ten beauty care companies [9]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index remained stable, outperforming the Shenwan A Index by 1.4 percentage points, while the Shenwan Personal Care Index fell by 1.8%, underperforming the Shenwan A Index by 0.3 percentage points [3][4]. Key Company Reviews - **Mao Geping (1318HK)**: Reported a revenue of 2.59 billion yuan for H1 2025, a year-on-year increase of 31%, with a net profit of 670 million yuan, up 36%. The color cosmetics segment saw a revenue of 1.42 billion yuan, while skincare generated 1.09 billion yuan, reflecting strong brand momentum [10][11]. - **Shangmei Co. (02145HK)**: Achieved a revenue of 4.108 billion yuan in H1 2025, a 17.3% increase, with a net profit of 556 million yuan, up 34.7%. The main brand, Han Shu, contributed significantly to growth, with a revenue of 3.344 billion yuan [16][17]. Investment Recommendations - Recommended companies include Shangmei Co., Porlaia, and Shanghai Jahwa, which have strong brand matrices and relatively low PE multiples. Other notable mentions are Marubi Biological and Mao Geping, which are positioned well to benefit from the rise of domestic beauty brands [10][19]. - The report suggests focusing on companies with strong R&D capabilities and product pipelines, particularly in the upstream medical beauty segment, with a recommendation for Aimeike [10][19]. Market Trends - The report notes a significant increase in online sales, with H1 2025 online revenue for Mao Geping reaching 1.297 billion yuan, a 39% year-on-year increase, marking a shift in consumer purchasing behavior towards online platforms [12][18]. - The overall cosmetics retail market showed a 4.5% growth in July 2025, indicating a robust recovery in consumer spending [23][26]. Strategic Developments - Porlaia's investment in Huazhi Xiao reflects a strategic move to enhance its multi-brand strategy and capitalize on the influence of Gen Z consumers [28]. - The report highlights the competitive landscape, noting that domestic brands are increasingly capturing market share, with a notable shift in consumer perception from "value for money" to "quality choice" [32].

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Group 1 - The company Sichuan Milan Baiyu Medical Beauty Hospital, a subsidiary of Langzi Co., is required to pay a total of 22.27 million yuan in taxes, including 16.53 million yuan in income tax and 5.74 million yuan in value-added tax and additional taxes for the years 2021 to 2023 [2] - The company plans to comply with tax regulations and pay the required taxes and penalties while also seeking to protect its legal rights under national tax laws [2] - The tax payment will impact the company's financials, reducing the net profit attributable to shareholders by approximately 30.82 million yuan in 2025, although it will not affect the normal operations of the company significantly [3]

证券日报网讯 9月4日晚间，朗姿股份发布公告称，2025年9月4日，公司全子公司四川米兰柏羽医学美 容医院有限公司（简称"四川米兰"）收到国家税务总局成都市税务局稽查局发来的《税务处理决定书》 （成税稽处〔2025〕55号），四川米兰需补缴2021年-2023年所得税1，653.14万元，增值税及附加税 573.95万元，合计2，227.09万元。四川米兰将按照国家税法的相关规定缴纳上述税款及滞纳金或者提供 相应的担保，但同时也拟将依据国家税法的相关规定，切实维护自身合法权益。 （编辑 任世碧） ...

Group 1 - The company announced that the tax payment and late fees will be recorded in the 2025 fiscal year, expected to reduce the net profit attributable to shareholders by approximately 30.82 million yuan [4] - The management of the company is taking the matter seriously and will enhance management practices, training, and awareness of tax laws to protect the interests of the company and its shareholders [4] - The tax issue will not have a significant impact on the company's normal operations [4] Group 2 - In the first half of the year, the company achieved operating revenue of 2.788 billion yuan, a year-on-year decrease of 4.30% [4] - The net profit attributable to shareholders was 274 million yuan, a year-on-year increase of 64.09%, while the net profit excluding non-recurring items was 136 million yuan, a year-on-year decrease of 2.70% [4] - The company reduced its holdings in RuYueChen, generating a net investment income of approximately 166.41 million yuan, which impacted the current net profit by 141.44 million yuan, accounting for 54.99% of the audited net profit for the last fiscal year [4] Group 3 - The company applied for a total of 110 million yuan in working capital loans from two banks, with guarantees provided by the controlling shareholder and actual controller [5]

Group 1 - The company, Langzi Co., announced that its subsidiary, Sichuan Milan Baiyu Medical Beauty Hospital Co., Ltd., received a tax processing decision from the Chengdu Taxation Bureau, requiring it to pay back taxes totaling 22.27 million yuan for the years 2021 to 2023 [2] - The breakdown of the tax liabilities includes 16.53 million yuan in income tax and 5.74 million yuan in value-added tax and additional taxes [2] - The repayment of these taxes and penalties will be recorded in the company's financial statements for the year 2025, which is expected to reduce the net profit attributable to shareholders by approximately 30.82 million yuan [2]